Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation

MeSH terms

• Alemtuzumab / therapeutic use
• Chimerism
• Graft vs Host Disease* / etiology
• Graft vs Host Disease* / prevention & control
• Hematopoietic Stem Cell Transplantation*
• Humans
• T-Lymphocytes
• Transplantation Chimera
• Transplantation Conditioning